Matches in Wikidata for { <http://www.wikidata.org/entity/Q91443894> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q91443894 description "article scientifique publié en 2019" @default.
- Q91443894 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91443894 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91443894 description "scientific article published on 21 November 2019" @default.
- Q91443894 description "wetenschappelijk artikel" @default.
- Q91443894 description "наукова стаття, опублікована 21 листопада 2019" @default.
- Q91443894 name "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 name "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 type Item @default.
- Q91443894 label "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 label "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 prefLabel "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 prefLabel "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 P1433 Q91443894-1A1B1926-7518-4A98-B789-24E91D926F48 @default.
- Q91443894 P1476 Q91443894-A7EAFB15-1D70-4D52-8751-1521AFE15DBD @default.
- Q91443894 P2093 Q91443894-2E21FA71-1782-48A8-A41A-70063AADA5D9 @default.
- Q91443894 P2093 Q91443894-476AEBF4-45D0-4725-A1A9-F65D2275430A @default.
- Q91443894 P2093 Q91443894-5DA23168-84B4-49DF-8D69-A53E8E6C678D @default.
- Q91443894 P2093 Q91443894-64FDC702-420C-4B7A-992D-C9053588016D @default.
- Q91443894 P2093 Q91443894-7B23F98C-BD7E-4E8E-A853-52106F3EB4F6 @default.
- Q91443894 P2093 Q91443894-7B81951D-F9A2-42CA-82C0-53E68C665342 @default.
- Q91443894 P2093 Q91443894-80103ECF-C2AD-4159-8B80-FE63916DCFE1 @default.
- Q91443894 P2093 Q91443894-9B8C3A09-58A8-484A-B684-794C9DB6B37E @default.
- Q91443894 P2093 Q91443894-A1FB554B-70A5-44B6-BF7A-519F54E3EEBD @default.
- Q91443894 P2093 Q91443894-B28F041D-B8FA-4714-80E6-BA000C4AB817 @default.
- Q91443894 P2093 Q91443894-BF97544E-FFFF-47F8-BE89-AF208C08E2C6 @default.
- Q91443894 P2093 Q91443894-C4231CFB-0C45-424A-87B6-716F42658FEE @default.
- Q91443894 P2093 Q91443894-CEA33276-F61D-4B3F-BB52-B167E57B616F @default.
- Q91443894 P2093 Q91443894-D7AF20ED-5E6E-4C9F-9904-8E02B3088B9A @default.
- Q91443894 P2093 Q91443894-E3922A95-60DB-4686-B929-2CB695BCD726 @default.
- Q91443894 P275 Q91443894-1d0a1782-0b35-444f-82d1-237d5dfd5e9c @default.
- Q91443894 P31 Q91443894-B52F908E-D098-440B-87A7-7A72E1606AA3 @default.
- Q91443894 P356 Q91443894-F1A92176-6169-4A3E-8312-051F3C8CDEFF @default.
- Q91443894 P433 Q91443894-459A38F0-AF95-4157-AD3D-A7528AA2585F @default.
- Q91443894 P478 Q91443894-4B92FEB3-10E6-4B9F-A372-083C7D2AFC76 @default.
- Q91443894 P577 Q91443894-FEDD5E0E-1920-497C-9144-F7C49CFFECC3 @default.
- Q91443894 P6216 Q91443894-2232abd5-74ef-414e-84a9-5652768310ac @default.
- Q91443894 P698 Q91443894-A3B1CC76-5F08-48BB-8C1A-238E7E23186A @default.
- Q91443894 P921 Q91443894-CCB67A39-9FE6-4A96-9630-151957F1C431 @default.
- Q91443894 P932 Q91443894-A4BC19EE-C0B0-41C2-BD5A-097E46D4FB5F @default.
- Q91443894 P356 CANCERS11121835 @default.
- Q91443894 P698 31766357 @default.
- Q91443894 P1433 Q27722963 @default.
- Q91443894 P1476 "Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial" @default.
- Q91443894 P2093 "Alexandra Langlais" @default.
- Q91443894 P2093 "Armelle Lavolé" @default.
- Q91443894 P2093 "Elisabeth Quoix" @default.
- Q91443894 P2093 "Elodie Maille" @default.
- Q91443894 P2093 "Emmanuel Bergot" @default.
- Q91443894 P2093 "Fatéméh Dubois" @default.
- Q91443894 P2093 "Franck Morin" @default.
- Q91443894 P2093 "Guénaëlle Levallet" @default.
- Q91443894 P2093 "Gérard Zalcman" @default.
- Q91443894 P2093 "Jean-Louis Pujol" @default.
- Q91443894 P2093 "Julien Hoflack" @default.
- Q91443894 P2093 "Laurence Bigay-Game" @default.
- Q91443894 P2093 "Martine Antoine" @default.
- Q91443894 P2093 "Maureen Keller" @default.
- Q91443894 P2093 "Virginie Westeel" @default.
- Q91443894 P275 Q20007257 @default.
- Q91443894 P31 Q13442814 @default.
- Q91443894 P356 "10.3390/CANCERS11121835" @default.
- Q91443894 P433 "12" @default.
- Q91443894 P478 "11" @default.
- Q91443894 P577 "2019-11-21T00:00:00Z" @default.
- Q91443894 P6216 Q50423863 @default.
- Q91443894 P698 "31766357" @default.
- Q91443894 P921 Q42824827 @default.
- Q91443894 P932 "6966477" @default.